Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, ...

Eli Lilly LLY announced that the FDA has approved a new maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) for adults ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction ...

Eli Lilly received approval from the Food and Drug Administration for a dermatitis treatment regimen that would allow patients to go longer between maintenance doses. The pharmaceutical company said ...

Among patients and caregivers of patients with AD, avoidance of adverse effects was prioritized as a treatment goal over symptom relief.

A topic dermatitis is a chronic condition that tends to rear its itchy head during certain periods before subsiding — for months, possibly, or even years. It particularly affects the insides of the ...

Eli Lilly (LLY) stock is in focus as the FDA approves a less frequent dosing regimen for maintenance dosing of the company's ...

Châtillon, France, June 8, 2026DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at ...

Managing this form of eczema while traveling? Discover potential triggers, such as allergens or a different climate, and how ...